Summary

Report Overview
The Global Squamous Non-Small Cell Lung Cancer Therapeutics Market reached US$4 billion in 2023 and is expected to reach US$ 8.06 billion by 2031, growing at a CAGR of 9.4% during the forecast period 2024-2031.
Squamous cell carcinoma of the lung, also known as squamous cell lung cancer, is a type of non-small cell lung cancer (NSCLC). Squamous cell lung tumors often occur in the central part of the lung or the main airway, such as the left or right bronchus. The principal causative agent of cellular transformation is smoking. Approximately 80% of lung cancer cases in men and 90% of patients in women are associated with smoking. 
SCC is more strongly associated with smoking than any other type of NSCLC. Other risk factors for squamous cell carcinoma of the lung include age, family history, exposure to second-hand smoke, and occupational exposure to minerals, metal particles, or asbestos. Clinical symptoms of NSCLCs include cough, chest pain, shortness of breath, blood in sputum, wheezing, hoarseness, recurring chest infections weight loss, loss of appetite, and fatigue.
Market Dynamics: Drivers
Increasing prevalence of squamous non-small cell lung cancer
The demand for the global squamous non-small cell lung cancer therapeutics market is driven by multiple factors. The rising prevalence of squamous non-small cell lung cancer propels the market growth. 
For instance, according to an article published by nih.gov in February 2024, in 2023, lung cancer was the third most common cancer in terms of incidence and the most common cause of cancer-related mortality in the US, as per the National Cancer Institute's Surveillance Epidemiology and End Results database.
Lung cancer incidence was estimated at 238,340 cases, accounting for 12% of the cancer burden in the US. The estimated mortality for lung cancer in 2023 was 127,070 deaths, constituting around 21% of all US cancer-related deaths. Approximately 85% of all lung cancers are NSCLCs. Adenocarcinoma and squamous cell carcinoma are the most common subtypes, accounting for 50% and 30% of NSCLC cases, respectively.
Restraints
Factors such as side effects associated with therapeutic drugs, high costs associated with the treatment, and stringent regulatory requirements for the approval of new therapies are expected to hamper the market.
Market Segment Analysis
The global squamous non-small cell lung cancer therapeutics market is segmented based on therapy type, end-user, and region.
The segment chemotherapy accounted for approximately 49.5% of the global squamous non-small cell lung cancer therapeutics market share
The chemotherapy segment is expected to hold the largest market share over the forecast period. In this segment, technological advancements, and rising funds for private manufacturers for clinical trials would drive this market.
For instance, in February 2024, the phase 2 clinical trials of sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer is performed. This was a single-arm, multicenter phase 2 clinical trial (ChiCTR1900021726) involving advanced squamous non-small cell lung cancer (sq-NSCLC) patients undergoing 2 cycles of nab-paclitaxel/carboplatin and sintilimab (anti-PD-1), followed by sintilimab maintenance therapy. The median progression-free survival (PFS) was 11.4 months (95% CI: 6.7-18.1), which met the pre-specified primary endpoint. 
Secondary endpoints included an objective response rate reaching 70.5% and a disease control rate of 93.2%, with a median duration of response of 13.6 months. The median overall survival was 27.2 months with treatment-related adverse events grades ≥3 occurring in 10.9% of patients. Predefined exploratory endpoints comprised relationships between biomarkers and treatment efficacy, and the association between circulating tumor DNA (ctDNA) dynamics and PFS.
Market Geographical Share
North America accounted for approximately 42.8% of the global squamous non-small cell lung cancer therapeutics market market share 
North America region is expected to hold the largest market share over the forecast period. The rising incidence of squamous non-small cell lung cancer, and growing awareness among people, in this region, help to propel the market.
For instance, according to an article published by cancer.org in January 2024, Lung cancer (both small cell and non-small cell) is the second most common cancer in both men and women in the United States. The American Cancer Society’s estimates for lung cancer in the US for 2024 are about 234,580 new cases of lung cancer (116,310 in men and 118,270 in women) and about 125,070 deaths from lung cancer (65,790 in men and 59,280 in women).
The chance that a man will develop lung cancer in his lifetime is about 1 in 16; for a woman, the risk is about 1 in 17. These numbers include both people who smoke and those who don’t smoke. For people who smoke, the risk is much higher, while for those who don't, the risk is lower.
Market Segmentation
By Therapy Type
Targeted Therapy
Immunotherapy
Chemotherapy
Others
By End-User
Hospitals
Specialty Clinics
Others
By Region
North America 
The U.S.
Canada
Mexico 
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe 
South America 
Brazil
Argentina
Rest of South America 
Asia-Pacific 
China
India
Japan
South Korea
Rest of Asia-Pacific 
Middle East and Africa
Market Competitive Landscape
The major global players in the global squamous non-small cell lung cancer therapeutics market include Genentech, Bristol Myers Squibb, Eli Lilly and Company, AstraZeneca, Pfizer Inc., Novartis AG, Merck Sharp & Dhome Corporation, Breckenridge Pharmaceutical Inc., Teva Pharmaceuticals Inc., Apotex Corporation among others.
Key Developments
In January 2024, a multi-cohort phase II study (NCT05329025) was done by Sun Yat-sen University Cancer Center to investigate the safety and efficacy of QL1706 (a single bifunctional MabPair product against PD-1 and CTLA-4) and chemotherapy with or without bevacizumab in this population. Overall, QL1706 plus chemotherapy, regardless of having bevacizumab, was generally tolerable and had promising antitumor activity for EGFR wild-type advanced NSCLC in a first-line setting. Moreover, QL1706 plus chemotherapy and bevacizumab showed favorable antitumor activity for patients who had EGFR-mutated NSCLC.
In November 2023, the PERLA phase 2 trials were performed by GSK Plc. The primary endpoint was the overall response rate. The DCT showed similar efficacy to PCT and demonstrates clinical efficacy as a first-line treatment for patients with metastatic non-squamous NSCLC.
In February 2024, Platinum-based dual-drug first-line chemotherapy is commonly employed in the treatment of patients with advanced non-small cell lung cancer (NSCLC), although its clinical efficacy is limited. Bevacizumab can antagonize vascular endothelial cell growth factor (VEGF), which inhibits tumor angiogenesis and prevents tumor invasion and development in the University of Science and Technology, China.  Combination therapy involving bevacizumab demonstrated improved antitumor effects compared to chemotherapy alone.
Why Purchase the Report?
To visualize the global squamous non-small cell lung cancer therapeutics market segmentation based on therapy type, end-user, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of global squamous non-small cell lung cancer therapeutics market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The global squamous non-small cell lung cancer therapeutics market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Therapy Type
3.2. Snippet by End-User
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Squamous Non-Small Cell Lung Cancer
4.1.1.2. Technological Advancements
4.1.1.3. Allotment of Funding for Research Works
4.1.2. Restraints
4.1.2.1. Side Effects Associated with Therapeutic Drugs
4.1.2.2. High Cost Associated with the Treatment
4.1.2.3. Stringent Regulatory Requirements
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Therapy Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
6.1.2. Market Attractiveness Index, By Therapy Type
6.2. Targeted Therapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Immunotherapy
6.4. Chemotherapy
6.5. Others
6.6. infection
6.7. Others
7. By End-User
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Specialty Clinics
7.4. Others
8. By Region
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.5.1. The U.S.
8.2.5.2. Canada
8.2.5.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.5.1. Germany
8.3.5.2. UK
8.3.5.3. France
8.3.5.4. Italy
8.3.5.5. Spain
8.3.5.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.5.1. Brazil
8.4.5.2. Argentina
8.4.5.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.5.1. China
8.5.5.2. India
8.5.5.3. Japan
8.5.5.4. South Korea
8.5.5.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9. Competitive Landscape
9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis
10. Company Profiles
10.1. Genentech *
10.1.1. Company Overview
10.1.2. Product Portfolio and Description
10.1.3. Financial Overview
10.1.4. Key Developments
10.2. Bristol Myers Squibb
10.3. Eli Lilly and Company
10.4. AstraZeneca
10.5. Pfizer Inc.
10.6. Novartis AG
10.7. Merch Sharp & Dhome Corporation
10.8. Breckenridge Pharmaceuticals Inc.
10.9. Teva Pharmaceuticals Inc.
10.10. Apotex Corporation (*LIST NOT EXHAUSTIVE)
11. Appendix
11.1. About Us and Services
11.2. Contact Us